Clinical trials: Covid19- Coronavirus- Sars-cov-2
Covid19, SARS-CoV Infection
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
Administration of Zinc and resveratrol or double placebo for a period of 5 days and will be monitored for a 14 day period in covid-19 positive patients in an outpatient setting
- Trial name
- Reszinate (NCT04542993)
- Testing
- Zinc Picolinate, Resveratrol
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Swedish Medical Center
COVID-19, Post COVID-19
Virtual Physical Rehabilitation for Patients Living with Long COVID
The purpose of this study is to investigate whether a timely, virtual home-based physical rehabilitation program for patients living with long COVID can improve functional mobility compared to usual care.
- Conditions
- COVID-19, Post COVID-19, Long COVID
- Trial name
- NCT05298878
- Testing
- Intervention Group: Virtual home-based rehabilitation plus usual outpatient care
- Where
- 2 sites in Canada
- Volunteers
- 132 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID, Pneumonia, Viral
High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy
Randomized, controlled study conducted in hospitalized patients with severe COViD-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation.
- Conditions
- COVID, Pneumonia, Viral, Coagulation Disorder
- Trial name
- COVID-19 HD (NCT04408235)
- Testing
- Enoxaparin
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
COVID-19
Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19
Study D822FC00005 will investigate the Phamacokinetics, Safety and tolerability of Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a Proton Pump Inhibitor, in the treatment of COVID-19.
- Trial name
- NCT04497948
- Testing
- Acalabrutinib
- Where
- 4 sites in Brazil
- Volunteers
- 9 people
- Sponsor
- Acerta Pharma BV
COVID-19
Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome
In patients infected by the SARS-Cov-2 Coronavirus a severely progressive disease requiring hospitalization in intensive care seems related to deregulation of cytokines with very high levels of IL-6, IL-2, IL-7, IL-10 and TNF-α.
- Trial name
- NCT04346017
- Testing
- Cytokines dosage, Complement dosage
- Where
- Belgium
- Volunteers
- 63 people
- Sponsor
- Francis Corazza
Coronavirus Disease (COVID-19), SARS-CoV-2 Infection
ImmuneSense™ COVID-19 Study
Coronavirus disease is of an urgent global priority. The purpose of ImmuneSense™ COVID-19 study is to evaluate the clinical performance and to provide data for clinical validation for the T-Detect™ SARS-CoV-2 (previously referred…
- Trial name
- NCT04583982
- Testing
- T-Detect™ SARS-CoV-2 Assay
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Adaptive Biotechnologies
Covid-19, SARS-CoV-2
A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine
This is a Phase 2/3, randomized, multicenter, double-blind, dose-response study to evaluate the safety, immunogenicity, and efficacy of UB 612 in 2 age groups, adults 18 to 59 and ≥60 years of age with or without comorbidities.
- Conditions
- Covid-19, SARS-CoV-2, Coronavirus
- Trial name
- NCT04683224
- Testing
- UB-612
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vaxxinity, Inc.
COVID-19, SARS-CoV-2
FREEDOM COVID-19 Anticoagulation Strategy
Coronavirus Disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has led to unprecedented morbidity and mortality in the modern era.
- Trial name
- FREEDOM COVID (NCT04512079)
- Testing
- Enoxaparin, Apixaban
- Where
- 21 sites in United States, Brazil and 3 more
- Volunteers
- 3,460 people
- Sponsor
- Valentin Fuster
Covid19, SARS (Severe Acute Respiratory Syndrome)
Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Coronavirus Disease 2019 (COVID-19) (previously called 2019-nCOV acute respiratory disease) is caused by SARS-CoV-2, a positive-sense single-stranded RNA virus of the coronavirus family.
- Trial name
- NCT04590274
- Testing
- Hydroxychloroquine, Vitamins and Minerals, Azithromycin
- Volunteers
- healthy volunteers welcome
- Sponsor
- International Brain Research Foundation
COVID-19 (Coronavirus Disease 2019), COVID-19 Pandemic
University Hospital of Ioannina COVID-19 (Coronavirus Disease 2019) Registry
COVID-19 (Coronavirus Disease 2019) Registry of University Hospital of Ioannina. Retrospective datasource registry with quantitative and qualitative patient data from the hospital medical records.
- Conditions
- COVID-19 (Coronavirus Disease 2019), COVID-19 Pandemic, COVID-19 Pneumonia, COVID-19 Respiratory Infection
- Trial name
- NCT05534074
- Where
- Greece
- Volunteers
- 2,500 people
- Sponsor
- University Hospital, Ioannina
Long Covid19, Exercise Intolerance
Restoring Energy With Sub-symptom Threshold Optimized Rehabilitation Exercise for Long COVID
The overall goal of this study is to find out if rehabilitation exercise can help people who have long COVID. Participants will be randomized by chance to receive either aerobic exercise or breathing exercise (combined with…
- Conditions
- Long Covid19, Exercise Intolerance, Riboflavin-Responsive
- Trial name
- RESToRE (NCT06172803)
- Testing
- Restoring Energy with Sub-symptom Threshold Aerobic Rehabilitation Exercise, Light Stretching/Breathing Exercises
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
COVID-19
Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults
This is a randomized, double-blind, parallel-controlled, equivalence trial, for evaluation of safety and immunogenicity, and batch-to-batch consistency of a recombinant adenovirus type-5-vectored Covid-19 vaccine Convidecia in…
- Trial name
- NCT05313646
- Testing
- batch 1 of Ad5-nCoV, batch 2 of Ad5-nCoV, batch 3 of Ad5-nCoV
- Where
- China
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Post-acute COVID-19 (PACS), or "long COVID" Syndrome
Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome
Use the Intermountain real-world MAb-treatment registry and control group to prospectively evaluate PACS symptoms at least 60 days after initial COVID-19 diagnosis.
- Trial name
- MAbPACs (NCT05013723)
- Testing
- Surveys
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Intermountain Health Care, Inc.
COVID-19
Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial
The purpose of this study is to evaluate the safety of Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells) after vaccination in people aged 18 and over.
- Trial name
- NCT06043388
- Testing
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Coronavirus Infections, SARS-CoV 2
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)
The Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) has been identified in Wuhan, China, which causes severe pulmonary complications and flu syndrome, which has spread rapidly to all continents.
- Conditions
- Coronavirus Infections, SARS-CoV 2, SARS (Severe Acute Respiratory Syndrome), Pulmonary Disease
- Trial name
- NCT04361461
- Testing
- Hydroxychloroquine Sulfate, Hydroxychloroquine Sulfate + Azythromycin
- Where
- Brazil
- Sponsor
- Apsen Farmaceutica S.A.
Quality of Life
QUALITATIVE SURVEY ABOUT NURSES FIRST WORK EXPERIENCE DURING COVID-19 PANDEMIC
During covid-19 pandemic an huge reorganization of all PiacenzaHospital was done to manage the increasing requests for hosptitalization. New nurses had to face first work experience in full pandemic Emergency.
- Trial name
- NCT05110859
- Testing
- in-depth individual interviews
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Azienda Unita Sanitaria Locale di Piacenza
Vitamin C, COVID-19
Lessening Organ Dysfunction With VITamin C - COVID-19
LOVIT-COVID is a multicentre concealed-allocation parallel-group blinded randomized controlled trial to ascertain the effect of high-dose intravenous vitamin C compared to placebo on mortality or persistent organ dysfunction at…
- Conditions
- Vitamin C, COVID-19, Hospitalized Patients
- Trial name
- LOVIT-COVID (NCT04401150)
- Testing
- Vitamin C, Control
- Where
- 2 sites in Canada
- Volunteers
- 392 people
- Sponsor
- Université de Sherbrooke
TB, COVID-19
Evaluation of the Truenat™MTB Plus/COVID-19 Test for TB (Tuberculosis) and COVID-19 (SARS-CoV2)
This is a prospective, multicentre study in which the accuracy of the Molbio Diagnostics Truenat™ MTB (Mycobacterium tuberculosis) Plus/COVID-19multiplex will be assessed for TB and COVID-19 case detection using prospectively…
- Trial name
- Truenat COMBO (NCT05405296)
- Testing
- Truenat™ MTB Plus/COVID-19
- Where
- Uganda
- Volunteers
- 1,984 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
COVID19
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 Mahmoud ELkazzaz(1),Tamer Haydara(2), Mohamed Abdelaal(3), Abedelaziz Elsayed(4) ,Yousry Abo-amer(5), Hesham Attia(6), Quan…
- Trial name
- Isotretinoin (NCT04353180)
- Testing
- Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment, Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment, Isotretinoin (13 cis retinoic acid ) capsules
- Where
- 2 sites in Egypt
- Volunteers
- 100,000 people
- Sponsor
- Kafrelsheikh University
Sars-CoV2, Covid19
TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
Interferon (IFN) lambda is one of the fundamental responses of the innate immune system. Peginterferon lambda is a long-acting form that has been studied extensively in human trials in viral hepatitis, confirming it safety and…
- Trial name
- NCT04967430
- Testing
- Peginterferon Lambda-1A
- Where
- Canada
- Volunteers
- 763 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.